OakChart

Evaxion A/S ADR

EVAXHealthcare·Biotechnology·Denmark·Nano·NASD·Nov 11 • 10:58 AM ET

2.99+0.13 (4.55%)
2026-11-11 17:00 CET
Market cap
23.85 USD m
Revenue, TTM
7.46 USD m
Net income, TTM
-8.68 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-1.05
P/E
-
Compare

Price

EVAX against its 20, 50 and 200-day averages
2050200earnings
3.003.504.004.503.2M6.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26EVAXclose 2.9920-day 3.1350-day 3.14200-day 3.452.9952w low

56.8% under the 52-week high of 6.92 on 9 Dec 2025. 52-week low 2.67 on 9 Nov 2026. Last 15 sessions, 49.8% high to low

Profile

EVAX
52-week range, 8% of the way up
2.676.92

Evaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen Moller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.

Employees46
IPOFeb 05, 2021
Beta0.56
ATR, 14d0.30
Rel volume0.26
Short float0.41%
Insider own19.22%
Inst own6.55%

Snapshot

6 groups

Valuation

Index-
Market Cap24.94M
Enterprise Value18.04M
Income-8.68M
Sales7.46M
Book/sh1.14
Cash/sh1.68
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees46
IPOFeb 05, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S3.34
P/B2.62
P/C1.78
P/FCF-
EV/EBITDA-
EV/Sales2.42
Quick Ratio5.06
Current Ratio5.06
Debt/Eq0.75
LT Debt/Eq0.69
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.05
EPS next Y-0.01
EPS next Q-0.01
EPS this Y-100.00%
EPS next Y62.50%
EPS next 5Y-
EPS past 3/5Y70.92% 51.86%
Sales past 3/5Y- -
EPS Y/Y TTM82.33%
Sales Y/Y TTM134.15%
EPS Q/Q42.42%
Sales Q/Q-100.00%
EarningsNov 19 BMO
EPS/Sales Surpr.0.00% -

Ownership

Insider Own19.22%
Insider Trans0.00%
Inst Own6.55%
Inst Trans0.42%
ROA-41.51%
ROE-110.21%
ROIC-53.95%
Gross Margin-
Oper. Margin-116.83%
Profit Margin-116.42%
SMA20-4.53%
SMA50-4.72%
SMA200-13.22%
Trades-

Technical

Shs Outstand8.34M
Shs Float6.74M
Short Float0.41%
Short Ratio0.12
Short Interest0.03M
52W High6.92 -56.79%
52W Low2.67 11.99%
Volatility12.17% 11.65%
ATR (14)0.30
RSI (14)47.95
Beta0.56
Rel Volume0.26
Avg Volume238.77K
Volume16,865

Performance

Perf Week0.67%
Perf Month8.33%
Perf Quarter-6.88%
Perf Half Y-28.12%
Perf YTD-37.32%
Perf Year-50.17%
Perf 3Y-92.03%
Perf 5Y-99.03%
Perf 10Y-
Recom1.00
Target Price12.25
Prev Close2.86
Price2.99
Change %4.55%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Feb 19, 2026InitiatedMMaxim GroupBuy$10+234.4%
Apr 02, 2024UpgradeLLadenburg ThalmannNeutral → Buy$8+167.6%
Feb 12, 2024InitiatedHH.C. WainwrightBuy$14+368.2%

Peers

Mkt cap
TickerCompanyMkt cap
ELTXElicio Therapeutics Inc43.59M
BNTXBioNTech SE ADR21.59B
ANIXAnixa Biosciences Inc103.60M
INOInovio Pharmaceuticals Inc141.38M
PDSBPDS Biotechnology Corp106.60M
ABSIAbsci Corp1.74B
MRNAModerna Inc99.76B
PCVXVaxcyte Inc10.73B
RXRXRecursion Pharmaceuticals Inc2.24B
GOVXGeovax Labs Inc1.11M

News

latest 14 of 206
  • Evaxion files amendment to registration statement related to 2025 EIB debt settlement agreement (GlobeNewswire) -8.33%
  • New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01 (GlobeNewswire) +8.70%
  • Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting (GlobeNewswire)
  • Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting (GlobeNewswire)
  • Evaxion receives International Prix Galien Award for AI-Immunology as best digital health solution (GlobeNewswire)
  • Loading…
  • EVAX Stock Heads For Best Week Since January 2025 As Cancer Vaccine Shows 89% Target Precision (Stocktwits)
  • Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 (GlobeNewswire)
  • Evaxion stock surges on 3-year melanoma vaccine trial data (Investing.com) +17.67%
  • INTC, EVAX, RCAT Stocks Move Higher Premarket Whats Driving The Rally? (Stocktwits)
  • Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 (GlobeNewswire)
  • Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting (GlobeNewswire)
  • Evaxion applies its AI-Immunology platform in autoimmune diseases (GlobeNewswire)
  • Evaxion AS (EVAX) (Q2 2026) Earnings Call Highlights: Strong EVX-01 Data and Field Validation ... (GuruFocus.com)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-19--0.010--0.001
2026Q22026-08-20-0.010-0.010-0.0100.000.001
2026Q12026-05-07-0.010-0.010-0.4370.000.001
2025Q42026-03-05-0.020-0.245-0.8930.000.002
2025Q32025-11-060.010-0.0100.7237.493.751
2025S12025-08-14-0.020-0.010-0.048.001
2025Q12025-05-27-0.010-0.705-0.2860.000.062
2024Q42025-04-01-0.070-1.955-3.1440.121.662
2024Q32024-10-31-0.200-1.567-1.7573.020.123
2024Q22024-08-14-0.600-1.267-5.7230.150.053
2024Q12024-05-280.150-5.4751.2770.050.042
2023Q42024-03-27-8.000-8.000-8.3430.070.002
2023Q32023-12-19-10.500-9.500-10.2090.000.001
2023Q22023-08-18-10.500-10.750-10.4880.000.002
2023Q12023-05-31-12.000-13.000-12.1550.000.003
2022Q42023-04-27-14.500-13.165-14.3580.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-48.500-47.750-46.6730.000.00
2021FY-63.000-58.500-62.8240.000.00
2022FY-49.000-48.000-49.0340.000.00
2023FY-40.500-38.667-40.5310.070.00
2024FY-0.200-4.080-9.8333.344.48
2025FY-0.020-0.450-0.0207.537.51
2026FY--0.040--0.00
2027FY--0.015--6.23
2028FY-0.000--15.41
2029FY-0.050--41.61
2030FY-0.060--50.77

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-202000.000.000.00
2026Q3S2026-05-072000.000.000.00
2026Q3S2026-03-062000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-10-011000.000.000.00
2026Q3S2025-09-301000.000.000.00
2026Q3S2025-09-291000.000.000.00
2026Q3S2025-09-281000.000.000.00
2026Q3S2025-09-271000.000.000.00
2026Q3S2025-09-261000.000.000.00
2026Q3S2025-09-251000.000.000.00
2026Q3S2025-09-241000.000.000.00
2026Q3S2025-09-231000.000.000.00

Estimate history

EPS, annual-17.068-34.549-46.673-62.824-49.034-40.531-9.833-1.206-1.0536
Period20182019202020212022202320242025TTM
EPS, quarterly-5.723-1.757-3.144-0.286-0.7750.723-0.893-0.437-0.446
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual000000.0733.3397.5517.46
Period20182019202020212022202320242025TTM
Sales, quarterly0.1543.0270.12100.0377.458000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.3240.3240.3240.4640.4830.7581.4038.348.34
Period20182019202020212022202320242025MRQ
Shares, quarterly1.0821.1151.4036.3176.3176.3178.348.348.34
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue7.467.553.340.070.000.000.000.000.00
Cost of Goods Sold Incl. D&A----0.570.340.110.080.07
Gross Profit-----0.57-0.34-0.11-0.08-0.07
Selling, General and Administrative Excl. Other16.1716.2017.4421.6924.6225.4516.5811.286.15
Research and Development10.279.6910.1411.5916.6219.4810.888.654.27
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-8.71-9.26-14.71-22.23-25.19-25.79-16.68-11.36-6.22
Interest Expense2.860.880.961.250.800.160.030.040.01
Unusual Expense-0.06-1.28-3.90-0.64-0.310.000.001.180.68
Net Income Before Taxes-9.62-8.64-11.34-22.95-23.95-24.67-16.69-12.02-6.26
Income Taxes-0.94-0.91-0.79-0.79-0.77-0.18-1.57-0.82-0.73
Consolidated Net Income-8.68-7.73-10.55-22.16-23.18-24.49-15.12-11.19-5.53
Net Income From Continuing Operations-8.68-7.73-10.55-22.16-23.18-24.49-15.12-11.19-5.53
Net Income-8.68-7.73-10.55-22.16-23.18-24.49-15.12-11.19-5.53
EPS (Recurring)-1.05-1.35-12.38-41.35-49.49-62.82-46.67-31.99-15.59
EPS (Basic, Before Extraordinaries)-1.05-1.21-9.83-40.53-49.03-62.82-46.67-34.55-17.07
EPS (Diluted)-1.05-1.21-9.83-40.53-49.03-62.82-46.67-34.55-17.07
EBITDA--8.65-14.10-21.62-24.62-25.45-16.58-11.28-6.15
Non-Operating Income (Expense)-1.130.220.43-0.101.731.280.020.560.65
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.240.140.370.741.072.681.841.61
Price To Sales Ratio3.474.051.36256.37-----
Operating Margin-116.83-122.66-440.55-30,407.00-----
Net Margin-116.42-102.38-316.00-30,308.37-----
Shares Outstanding8.348.341.400.760.480.460.320.320.32
Market Capitalization23.8523.855.9319.0741.19102.5684.09--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.007.460.040.000.123.03
Cost of Goods Sold Incl. D&A0.000.000.00--0.00--
Gross Profit0.000.000.00--0.00--
Selling, General and Administrative Excl. Other3.843.834.054.454.443.874.124.76
Research and Development2.332.312.563.082.192.162.242.62
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.84-3.83-4.053.01-4.40-3.87-4.00-1.74
Interest Expense0.160.331.011.351.250.400.450.39
Unusual Expense-0.060.000.000.000.000.000.000.00
Net Income Before Taxes-3.93-3.86-6.174.33-5.09-1.77-3.88-2.04
Income Taxes-0.20-0.22-0.26-0.26-0.20-0.19-0.27-0.10
Consolidated Net Income-3.72-3.64-5.914.60-4.90-1.58-3.60-1.94
Net Income From Continuing Operations-3.72-3.64-5.914.60-4.90-1.58-3.60-1.94
Net Income-3.72-3.64-5.914.60-4.90-1.58-3.60-1.94
EPS (Recurring)-0.45-0.44-0.890.72-0.78-0.29-3.14-1.76
EPS (Basic, Before Extraordinaries)-0.45-0.44-0.890.72-0.78-0.29-3.14-1.76
EPS (Diluted)-0.45-0.44-0.890.72-0.78-0.29-3.14-1.76
Non-Operating Income (Expense)0.020.31-1.112.680.552.490.570.08
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Price To Sales Ratio3.474.144.213.144.863.101.455.20
Operating Margin---40.35-11,729.73--3,298.36-57.37
Net Margin---61.64-13,056.75--2,974.59-64.14
Shares Outstanding8.348.348.346.326.326.321.401.12
Market Capitalization23.8531.0330.1323.753.442.175.9317.34

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments23.235.955.5813.1832.175.839.567.43
Short Term Receivables1.051.861.071.311.901.790.930.77
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets0.620.961.692.490.643.320.470.18
Total Current Assets24.908.778.3516.9934.7110.9510.968.38
Net Property, Plant & Equipment3.323.514.344.685.170.460.130.13
Total Investments and Advances0.000.000.000.000.000.000.000.00
Long-Term Note Receivable0.000.040.030.210.00---
Intangible Assets0.000.000.000.000.090.100.000.00
Deferred Tax Assets----0.000.26--
Other Assets0.180.160.170.160.190.190.000.00
Total Assets28.4112.4912.8922.0340.1611.9711.088.51
Short Term Debt Incl. Current Port. of LT Debt0.550.470.480.440.440.020.048.64
Accounts Payable2.192.972.692.092.853.671.230.34
Other Current Liabilities1.520.933.911.241.041.230.450.44
Total Current Liabilities4.264.377.083.764.324.931.729.42
Long Term Debt6.959.6310.389.823.250.000.000.02
Provision for Risks Charges0.160.140.150.140.150.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.00
Total Liabilities11.3714.1417.6213.727.734.931.729.44
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity17.04-1.65-4.738.3032.447.049.36-0.93
Total Shareholders Equity17.04-1.65-4.738.3032.447.049.36-0.93
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity17.04-1.65-4.738.3032.447.049.36-0.93
Total Liabilities & Stockholders Equity28.4112.4912.8922.0340.1611.9711.088.51
Book Value Per Share2.04-1.18-6.2417.2069.9021.7228.90-2.87
Tangible Book Value Per Share2.04-1.18-6.2417.2069.7021.4228.90-2.87
Full-Time Employees4646496361353620
Price to Book Ratio2.50-3.59-6.983.043.165.05--
Return on Assets-37.81-83.16-126.93-74.55-93.97-131.21-114.23-
Return on Equity-100.48--1,239.89-113.80-124.09-184.40-265.51-
Return on Invested Capital-32.22-132.27-391.79-127.94-68.63-214.85-119.55-
Quick Ratio5.852.011.184.518.032.226.360.89
Current Ratio5.852.011.184.518.032.226.360.89

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income--7.73-10.55-22.16-23.18-24.49-15.12-11.19-5.53
Depreciation-0.620.610.620.570.340.110.080.07
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00
Other Funds (Non Cash)-0.61-3.492.26-0.301.022.283.512.50
Funds from Operations--6.51-13.44-19.28-22.91-23.13-12.74-7.60-2.96
Extraordinary Item-0.000.000.000.000.000.000.000.00
Changes in Working Capital--0.140.521.56-2.881.240.220.570.98
Cash from Operating Activities--6.65-12.92-17.72-25.79-21.90-12.52-7.02-1.98
Capital Expenditures--0.010.00-0.09-0.29-1.36-0.40-0.06-0.01
Net Assets From Acquisitions-0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments--0.00-0.00-0.010.020.030.000.000.00
Purchase of Investments--0.00-0.00-0.010.000.000.000.000.00
Sale Or Maturity of Investments-0.00--0.020.030.000.000.00
Other Uses-0.000.000.000.000.000.000.000.00
Other Sources-0.000.000.000.000.000.000.000.00
Cash from Investing Activities--0.01-0.00-0.09-0.27-1.33-0.40-0.06-0.01
Cash Dividends Paid-0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Change in Capital Stock-23.2314.1811.340.4350.018.959.431.09
Repurchase of Common Pref Stock-0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock-23.2314.1811.340.4350.018.959.431.09
Proceedsfrom Stock Options-23.2314.1811.340.4350.018.959.431.09
Issuance or Reduction of Debt, Net--0.40-0.74-0.317.73-0.060.000.157.99
Change in Long Term Debt--0.40-0.74---0.060.000.157.99
Issuance of Long Term Debt-0.000.06--0.000.000.157.99
Reduction of Long Term Debt--0.40-0.80---0.060.000.000.00
Net Financing Active Other Cash Flow-0.000.000.000.000.000.000.000.00
Other Financing Activities Uses-0.000.000.000.000.000.000.000.00
Cash from Financing Activities-22.4813.1110.717.8649.738.889.519.02
Exchange Rate Effect-1.520.18-0.51-0.79-0.210.29-0.29-0.08
Net Change in Cash-17.330.37-7.61-18.9926.29-3.752.136.96
Free Cash Flow--6.66-12.92-17.81-26.08-23.20-12.88-7.09-1.98

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments14.0018.4423.2310.5714.7517.84
Short Term Receivables1.86-1.05-3.43-
Inventories0.00-0.00-0.00-
Other Current Assets0.00-0.62-0.00-
Total Current Assets15.86-24.90-18.18-
Net Property, Plant & Equipment2.92-3.32-3.62-
Total Investments and Advances0.00-0.00-0.00-
Intangible Assets0.00-0.00-0.00-
Other Assets0.18-0.18-0.18-
Total Assets19.3823.6428.4129.7422.4525.24
Short Term Debt Incl. Current Port. of LT Debt0.54-0.55-0.54-
Accounts Payable1.59-2.19-2.50-
Other Current Liabilities1.00-1.52-2.29-
Total Current Liabilities3.13-4.26-5.32-
Long Term Debt6.56-6.95-10.74-
Provision for Risks Charges0.15-0.16-0.16-
Other Liabilities0.0010.430.0013.140.0014.90
Total Liabilities9.8510.4311.3713.1416.2214.90
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity9.5313.2117.0416.606.2310.34
Total Shareholders Equity9.5313.2117.0416.606.2310.34
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity9.5313.2117.0416.606.2310.34
Total Liabilities & Stockholders Equity19.3823.6428.4129.7422.4525.24
Book Value Per Share1.141.582.042.630.991.64
Tangible Book Value Per Share1.141.582.042.630.991.64
Full-Time Employees--46---
Price to Book Ratio2.501.824.843.81-2.081.60
Return on Assets-41.51-40.32-38.12-24.41-63.81-55.62
Return on Equity-110.21-83.69-101.30-65.78-321.47-205.74
Return on Invested Capital-23.14--24.65--28.85-
Quick Ratio5.06-5.85-3.42-
Current Ratio5.06-5.85-3.42-

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 3.34M 2025: 7.53M
Denmark2024: 3.34M 2025: 7.53M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.41%0.0M6.7M231.34K
2026-10-150.99%0.1M6.7M200.82K
2026-09-300.75%0.1M6.7M198.52K
2026-09-150.80%0.1M6.7M198.43K
2026-08-310.84%0.1M6.7M194.00K
2026-08-140.31%0.0M6.7M22.33K
2026-07-310.25%0.0M6.7M25.02K
2026-07-150.31%0.0M6.7M30.21K
2026-06-300.44%0.0M6.7M30.47K
2026-06-150.45%0.0M6.7M30.68K
2026-05-290.37%0.0M6.7M31.60K
2026-05-150.48%0.0M6.7M30.76K
2026-04-300.53%0.0M6.7M34.23K
2026-04-150.45%0.0M6.7M43.85K
2026-03-310.56%0.0M6.7M48.19K
2026-03-130.86%0.1M6.7M63.84K
2026-02-270.78%0.1M6.7M75.79K
2026-02-131.61%0.1M5.1M85.61K
2026-01-301.33%0.1M5.1M103.65K
2026-01-152.07%0.1M5.1M185.22K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-09SEC
2026-11-09F-1/ASEC
2026-11-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-06SEC
2026-11-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-04SEC
2026-11-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-04SEC
2026-11-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-03SEC
2026-10-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-30SEC
2026-10-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-23SEC
2026-10-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-19SEC
2026-10-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-02SEC
2026-09-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-14SEC
2026-09-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-04SEC
2026-08-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-20SEC
2026-08-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-17SEC
2026-08-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-14SEC
2026-07-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-17SEC
2026-07-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-12SEC
2026-07-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-01SEC
2026-06-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-12SEC
2026-06-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-11SEC
2026-05-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-12SEC
2026-05-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-07SEC
2026-05-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-04SEC
2026-04-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-27SEC
2026-04-243Initial statement of beneficial ownership of securities2026-04-16SEC
2026-04-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-21SEC
2026-04-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-17SEC
2026-04-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-17SEC
2026-04-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-16SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Merck & Co., Inc.14.56%
Ikarian Capital, LLC0.90%
Rathbones Group PLC0.55%
CITADEL ADVISORS LLC0.44%
RENAISSANCE TECHNOLOGIES LLC0.41%
Annis Gardner Whiting Capital Advisors, LLC0.36%
J. Safra Sarasin Holding AG0.27%
JANE STREET GROUP, LLC0.25%
RHUMBLINE ADVISERS0.24%
BOOTHBAY FUND MANAGEMENT, LLC0.22%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.01%

OakChart. EVAX. Cached 15 minutes.

Some panels did not load: insider.